Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc13.5 | Anterior and Posterior pituitary 2 | ECE2019

Pan-genomic classification of pituitary adenomas

Neou Mario , Villa Chiara , Armignacco Roberta , Jouinot Anne , Septier Amandine , Raffin-Sanson Marie-Laure , Perlemoine Karine , Bernier Michele , Baussart Bertrand , Bertherat Jerome , Gaillard Stephan , Assie Guillaume

Pituitary adenomas, now called pituitary neuroendocrine tumors (PitNETs), vary in histological type, secretion, invasion and growth speed. A World Health Organization (WHO) histo-prognostic classification was released in 2017. Pituitary tumorigenesis is largely unexplained. Rare germline mutations (MENIN, AIP), and common somatic mutations in somatotroph (GNAS) and corticotroph (USP8) are reported. Recently, genomic analyses have been report...

ea0063gp243 | Anterior and Posterior Pituitary | ECE2019

Histological classification of pituitary neuroendocrine tumors: genomic insights on cell lineage

Villa Chiara , Neou Mario , Armignacco Roberta , Jouinot Anne , Septier Amandine , Perlemoine Karine , Bernier Michele , Laure Raffin-Sanson Marie , Baussart Bertrand , Bertherat Jerome , Gaillard Stephan , Assie Guillaume

The 2017 World Health Organization (WHO) classification of pituitary adenomas is based on cell lineage and transcription factors (TFs). Pituitary progenitors expressing Pit-1 are driven towards the somato-lacto-thyrotroph differentiation, T-Pit towards corticotroph, and SF-1 towards gonadotroph. We recently generated a multi-genomic classification of pituitary neuroendocrine tumors (PitNETs) (abstract submitted to ECE2019 by Neou M.). Transcriptome classification identified si...

ea0022p383 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

Raverot Gerald , Sturm Nathalie , De Fraipont Florence , Caron Philippe , Muller Marie , Cortet-Rudelli Christine , Salenave Sylvie , Assaker Richard , Dufour Henry , Gaillard Stephan , Francois Patrick , Jouanneau Emmanuel , Bernier Michele , Figarella-Branger Dominique , Maurage Claude-Alain , Trouillas Jacqueline , Borson-Chazot Francoise , Brue Thierry

Context: To date ten publications reporting only 16 patients with pituitary aggressive tumors or carcinomas treated with temozolomide are available. Expression of O6-methylguanine-DNA-methyltranferase (MGMT), a DNA repair protein implicated in the resistance to temozolomide, was studied in only 10 out of these 16 patients. It has been suggested that low expression of MGMT could predict temozolomide efficacy.Objective: The aim of this st...